Lineage Cell Therapeutics LCTX
NYSE LCTX
$0.95 -0.02 (-1.69%)
As of: Sep 29, 2026 · 3:59 PM EDT

Lineage Cell Therapeutics (LCTX) Acquisitions (2010 - 2019)

Updated

Lineage Cell Therapeutics' Acquisitions came in at $3.12 million for FY2019.

Analysis

Lineage Cell Therapeutics (LCTX) Acquisitions (2010 - 2019) Analysis & Trends

Going back to FY2010, Lineage Cell Therapeutics' Acquisitions data covers 4 years.

  • The FY2019 figure represents the lowest annual Acquisitions since FY2012.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Acquisitions (Qtr)
1 Johnson & Johnson 655.56 Bn 574.09 Bn 17.26 Bn -17.24 Bn
2 AbbVie 470.94 Bn 444.10 Bn 12.70 Bn -
3 Merck 367.14 Bn 321.57 Bn 12.21 Bn -
4 Novartis Ag 280.33 Bn 236.20 Bn 11.24 Bn -23.00 Mn
5 Astrazeneca 257.78 Bn 231.34 Bn 12.86 Bn -
6 Amgen 226.04 Bn 181.44 Bn 7.24 Bn -
7 Gilead Sciences 188.89 Bn 163.01 Bn 6.22 Bn 11.21 Bn
8 Pfizer 163.75 Bn 110.70 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 133.68 Bn 105.69 Bn 2.84 Bn -
10 Lineage Cell Therapeutics 245.32 Mn 43.73 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2019 3.12 Mn
Jun 30, 2012 292,387.00
Mar 31, 2011 246,850.00
Dec 31, 2010 222,766.00
API Access

Lineage Cell Therapeutics Acquisitions API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=acquisitions&ticker=LCTX&period=max&api_key=YOUR_API_KEY